Study of DAT-2645 for advanced solid tumors with DNA repair defects
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests an experimental pill (DAT-2645) for people with advanced or metastatic solid tumors that have DNA repair problems, such as BRCA gene mutations. The drug targets a repair mechanism that these cancer cells need, potentially slowing or stopping their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your tumor must have a specific DNA repair problem (like a BRCA gene change), confirmed by a test.
- You must have tried standard treatment, or it isn't working, or you can't tolerate it.
- You need to have at least one tumor that can be measured on a scan.
- You must be well enough to be up and about (performance status 0-2).
- You cannot have had certain cancer treatments within 2-4 weeks before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
This trial tests a new oral drug (DAT-1604) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if it is safe, how the body processes it, and whether it can shrink or slow tumor growth.
This Phase I/II trial tests an investigational treatment in people with advanced solid tumors that have grown despite standard therapy, or where standard options aren’t available. In later Phase II, the trial mainly enrolls patients whose tumor shows a specific DNA repair problem (DDR defect).
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.